PMID- 9535024
OWN - NLM
STAT- MEDLINE
DCOM- 19980513
LR  - 20131121
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 123
IP  - 5
DP  - 1998 Mar
TI  - Histamine-induced biphasic macromolecular leakage in the microcirculation of the 
      conscious hamster: evidence for a delayed nitric oxide-dependent leakage.
PG  - 943-51
AB  - 1. Late effects (up to 3 h) of intravenously-injected histamine on FITC-dextran 
      extravasation were investigated in the conscious hamster, by use of 
      computer-assisted image analysis of fluorescence distribution in a microscopic 
      window of dorsal skin fold preparations. This analysis allowed measurement of 
      local (skin) and general (all organs) extravasations caused by a bolus injection 
      of histamine (1 mg kg(-1), i.v.) 2. Histamine doses higher than 0.01 mg kg(-1) 
      caused biphasic local and general extravasations. Initial phases developed fully 
      within 15 min (for local) and 60 min (for general) and were followed by late 
      phases beginning 90 min after histamine injection. Although the initial and late 
      phases of histamine-induced extravasations had differential apparent reactivities 
      to the autacoid, all the effects of histamine on the microcirculation (1 mg 
      kg[-1]) were inhibited by pyrilamine (1 mg kg(-1), i.v.) but not by cimetidine (1 
      mg kg(-1), i.v.). 3. Pretreatment with N(G)-monomethyl-L-arginine (L-NMMA, 30 mg 
      kg(-1), i.v.) or N(G)-nitro-L-arginine methyl ester (L-NAME, 100 mg kg(-1), i.v.) 
      did not affect the initial phases but did prevent the late phases of local and 
      general extravasations triggered by 1 mg kg(-1) histamine. The inhibitory effects 
      of L-NAME were reversed by L-arginine (30 mg kg[-1]) but not by D-arginine (30 mg 
      kg[-1]) according to the enantioselectivity of nitric oxide synthase (NOS). A 
      late NO-mediated venular dilatation occurred in response to plasma histamine. 4. 
      A low dose of aminoguanidine (1 mg kg(-1), i.v.), a selective inhibitor of the 
      inducible isoform of NOS (iNOS), mimicked the inhibitory effects of L-NAME on the 
      late phases of histamine-induced macromolecular extravasations and venular 
      dilatation. 5. Pretreatment with dexamethasone (1 mg kg(-1), i.v.) prevented both 
      the initial and late phases of histamine-induced extravasations. Fucoidan (1 or 
      25 mg kg(-1), i.v.) prevented the late phases without affecting initial phases, 
      consistent with a role for leukocytes adhesion in the development of the late 
      NO-mediated effects of histamine. 6. We conclude that intravenous injection of 
      histamine triggers a biphasic inflammatory cascade via initial activation of H1 
      receptors which induces a late NO-mediated PMN-dependent extravasation process.
FAU - Gimeno, G
AU  - Gimeno G
AD  - Service de Pharmacologie, Laboratoire Innothera, Arcueil, France.
FAU - Carpentier, P H
AU  - Carpentier PH
FAU - Desquand-Billiald, S
AU  - Desquand-Billiald S
FAU - Hanf, R
AU  - Hanf R
FAU - Finet, M
AU  - Finet M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Guanidines)
RN  - 0 (Polysaccharides)
RN  - 27JT06E6GR (omega-N-Methylarginine)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - 820484N8I3 (Histamine)
RN  - 9072-19-9 (fucoidan)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type II)
RN  - SCQ4EZQ113 (pimagedine)
RN  - V55S2QJN2X (NG-Nitroarginine Methyl Ester)
SB  - IM
MH  - Animals
MH  - Capillary Permeability/*drug effects/physiology
MH  - Cricetinae
MH  - Dexamethasone/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Enzyme Inhibitors/pharmacology
MH  - Guanidines/pharmacology
MH  - Histamine/*pharmacology
MH  - Male
MH  - Mesocricetus
MH  - Microcirculation/*drug effects
MH  - NG-Nitroarginine Methyl Ester/pharmacology
MH  - Nitric Oxide/*physiology
MH  - Nitric Oxide Synthase/antagonists & inhibitors
MH  - Nitric Oxide Synthase Type II
MH  - Polysaccharides/pharmacology
MH  - omega-N-Methylarginine/pharmacology
PMC - PMC1565232
EDAT- 1998/04/16 00:00
MHDA- 1998/04/16 00:01
PMCR- 1999/03/01
CRDT- 1998/04/16 00:00
PHST- 1998/04/16 00:00 [pubmed]
PHST- 1998/04/16 00:01 [medline]
PHST- 1998/04/16 00:00 [entrez]
PHST- 1999/03/01 00:00 [pmc-release]
AID - 0701676 [pii]
AID - 10.1038/sj.bjp.0701676 [doi]
PST - ppublish
SO  - Br J Pharmacol. 1998 Mar;123(5):943-51. doi: 10.1038/sj.bjp.0701676.